Presumed Equivalent: How Adult Drug Data Is Quietly Standing In for Pediatric Evidence

When a pediatric oncologist selects a chemotherapy regimen for a seven-year-old, the dosing guidance she consults was almost certainly derived from trials conducted in adults. She may adjust by weight or body surface area, apply a developmental correction factor drawn from limited pharmacokinetic modeling, and proceed. This is not negligence. In the majority of cases, it is the only option the evidence base provides. The question that deserves far more scrutiny than it currently receives is whether that evidence base was ever adequate to begin with.

The United States has made measurable legislative progress on pediatric drug research. The Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act together created mechanisms that incentivize and, in some cases, mandate pediatric study submissions to the FDA. Yet a substantial portion of drugs prescribed to children today—estimates in the literature have ranged from one-third to more than half, depending on the therapeutic area and patient population—are used under conditions that were never rigorously tested in pediatric subjects. The regulatory instrument that makes this legally permissible is known as pediatric extrapolation, and its assumptions deserve considerably more clinical scrutiny than they typically receive.

The Extrapolation Framework and Its Assumptions

Pediatric extrapolation, as defined by FDA guidance, permits sponsors to rely on adult efficacy data when the course of a disease and the drug's effects are sufficiently similar between adults and children. Under this framework, a sponsor may conduct limited pediatric pharmacokinetic studies—establishing how a drug moves through a child's body—and use that data to derive a dose presumed to produce adult-equivalent exposure. Full pediatric efficacy trials are not required.

The logic is not without merit in select circumstances. For certain conditions with well-characterized and biologically consistent pathophysiology across age groups, extrapolation may be scientifically defensible. The problem is that the framework has been applied broadly, across therapeutic areas and developmental stages where the physiological differences between children and adults are clinically significant, not incidental.

Children are not pharmacologically uniform. A neonate processes drugs through enzyme systems that are functionally immature. A toddler has a proportionally larger liver relative to body mass than an adult, affecting first-pass metabolism in ways that weight-based scaling does not capture. An adolescent undergoing puberty experiences hormonal shifts that alter drug receptor sensitivity and metabolic rates simultaneously. Treating these stages as points on a continuous adult curve is a simplification that the evidence does not consistently support.

The Economics of Pediatric Neglect

The persistence of this evidence gap is not primarily a scientific failure. It is an economic one. Pediatric populations are smaller, more heterogeneous by developmental stage, and ethically more complex to enroll in interventional trials. Recruitment is slower, parental consent requirements are more demanding, and assent protocols for older children add procedural layers that increase per-subject costs substantially.

For manufacturers, the calculus is straightforward. Adult markets are larger, trials are faster, and the regulatory incentives for pediatric study—most notably the six-month patent exclusivity extension offered under existing legislation—are insufficient to offset development costs for drugs whose primary commercial value lies in adult indications. The result is a systematic underinvestment that is entirely rational from a business standpoint and deeply problematic from a public health standpoint.

Academic medical centers and children's hospitals have attempted to fill portions of this gap through investigator-initiated trials and consortium-based research networks. The Pediatric Trials Network, funded through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, has generated important pharmacokinetic and safety data for off-patent drugs commonly used in pediatric populations. These efforts are valuable. They are also chronically underfunded relative to the scope of the problem.

Where Extrapolation Breaks Down Clinically

The real-world consequences of this framework become visible in specific therapeutic contexts. Pediatric psychopharmacology offers one of the more extensively documented examples. Multiple antidepressants and antipsychotics were prescribed to children and adolescents based on adult efficacy data before pediatric trials revealed either diminished efficacy or safety signals—including the black-box warning on suicidality risk in younger patients—that were not apparent from adult data alone.

Similar patterns have emerged in pediatric cardiology, infectious disease, and pain management. Dosing regimens for certain analgesics have been associated with respiratory complications in children that adult studies did not predict. Antibiotic dosing derived from adult pharmacokinetic models has, in some cases, produced subtherapeutic exposures in pediatric patients, with implications for both treatment failure and resistance development.

These are not isolated anecdotes. They represent a recurring structural pattern: adult data is presumed sufficient, pediatric extrapolation is applied, and the safety or efficacy signal that would have emerged from dedicated pediatric trials surfaces instead through postmarket surveillance, adverse event reporting, or—in the most troubling cases—accumulated clinical experience.

Regulatory Reform and Its Limits

The FDA has acknowledged the limitations of the extrapolation framework and has issued updated guidance documents attempting to clarify when extrapolation is and is not appropriate. The agency has also expanded requirements for pediatric study plans submitted as part of the drug development process. These are meaningful steps.

However, the structural incentive problem remains largely unaddressed. Guidance documents do not change the economics of pediatric trial design. Mandatory pediatric study requirements apply primarily to new molecular entities and new indications, leaving a substantial backlog of older, widely used drugs without adequate pediatric data. And the six-month exclusivity extension, while valuable for high-revenue products, does not meaningfully move the needle for drugs with limited commercial potential regardless of their clinical importance to pediatric populations.

Some researchers and policy advocates have proposed more aggressive mechanisms: expanded public funding for pediatric pharmacology research, adaptive trial designs that reduce enrollment burdens, and regulatory pathways that create stronger consequences for sponsors who seek pediatric labeling extensions without providing proportionate evidence. These proposals have gained limited legislative traction.

A Standard of Evidence That Children Deserve

The central issue is one of evidentiary standards. Clinical research in the United States operates on a foundational principle that treatments should be evaluated in the populations that will receive them. Pediatric extrapolation, as currently applied, creates a sanctioned exception to that principle—one justified by practical constraint but rarely interrogated for its cumulative clinical cost.

Healthcare professionals prescribing to pediatric patients deserve better than dosing guidance assembled from adult pharmacokinetics and developmental correction factors. Children's hospitals deserve access to evidence generated in patients who resemble the ones in their wards. And pediatric patients, who bear the consequences of this evidence gap most directly, deserve a research enterprise that treats their physiology as worthy of dedicated study rather than as a derivative of adult biology.

Closing this gap will require coordinated action across regulatory agencies, research funders, academic medical centers, and the pharmaceutical industry. It will also require a more explicit acknowledgment, within the clinical research community, that the current framework is not a temporary inconvenience but a persistent structural failure—one that has been accommodated for long enough.